KoreaMed, a service of the Korean Association of Medical Journal Editors (KAMJE), provides access to articles published in Korean medical, dental, nursing, nutrition and veterinary journals. KoreaMed records include links to full-text content in Synapse and publisher web sites.
The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivolumab is used...
A 54-year old man diagnosed with advanced hepatocellular carcinoma began treatment with sorafenib. After 3 weeks of treatment, he complained of abdominal pain and nausea. Abdominal sonography showed multiple hepatic...
The pathogenesis of hepatocellular carcinoma (HCC) is a complex process. During the last decade, advances in genomic technologies enabled delineation of the genomic landscape of HCC, resulting in the identification...
Hepatocellular carcinoma (HCC) has become an important indication for liver transplantation in Korea. Even though the Milan criteria have been accepted as the gold standard in deceased donor liver transplantation,...
Lee KK, Youn YC, Hwang JK, Park JH, Kim JI, Yoo YK, Moon IS, Kim DG
KMID: 2083319
Korean J Hepatobiliary Pancreat Surg.
2009 Sep;13(3):171-178.
PURPOSE: The purpose of this study was to evaluate the possibility of expanding the indication for living donor liver transplantation (LDLT) for treatment of hepatocellular carcinoma (HCC), beyond the Milan...
BACKGROUND: Surgical resection is the mainstay for treatment of HCC. However, resction is often not feasible in patients with advanced HCC. Patients excluded from surgery, may be treated with systemic...
PURPOSE: Hepatocellular carcinoma (HCC) is the most common form of primary hepatic carcinoma and is considered to be a highly malignant tumor with poor prognosis. We evaluated the efficacy and...